The shareholders of Genomtec SA at the Extraordinary General Meeting on 12 March 2025 voted on a resolution to increase the Company’s share capital by issuing 1,542,556 new ordinary bearer shares of series P, with the entire exclusion of the subscription rights of the existing shareholders. Genomtec will gain approximately PLN 11 million (gross) from the share issue, which will secure the Company’s financial position for the coming months and will allow for further development of projects and efficient implementation of the M&A process.
“We are pleased that the Shareholders at the EGM supported the resolution on the issue of new shares. The issue directed to 5HT actually crowns the process in which this entity conducted a share offer, as a result of which a number of investors joined our shareholding. The funds obtained from the share issue will reach Genomtec within a few weeks and will secure our financial needs for the key period in which we are conducting advanced negotiations with potential partners in the commercialization of our projects. The talks to date have resulted in the signing of confidentiality agreements with partners from Europe and North America. At the same time, we are observing growing interest from Asian markets. Therefore, in parallel with Clairfield’s work focused on the sale of Genomtec ID, we have decided to establish additional cooperation with the renowned transaction advisor Lynx Financial based in Shanghai, which will support the process of preparing and selling the OncoSNAAT project on Asian markets.” – says Miron Tokarski, President of the Management Board of Genomtec SA
Genomtec SA concluded an investment agreement with the Company’s Shareholder – 5HT Fundacja Rodzinna on February 12 this year. According to the agreement, the Shareholder sold 1,342,556 existing and admitted to trading shares of the Company at a price of PLN 7 per share, which were acquired by a total of 13 investors. Then, in accordance with the resolution of the EGM, the Company will be obliged to offer 1,542,556 Shares of the new issue for the Shareholder to take up at a unit issue price equal to the price of shares sold in ABB.
The company’s flagship project is the Genomtec ID mobile diagnostic system. The platform consists of an analyzer and a reaction card with integrated genetic tests. The second OncoSNAAT project involves developing technology for detecting mutations in the oncological area, which indicate the most effective therapy. At the end of January this year, Genomtec filed a patent application in the OncoSNAAT oncological project for an invention in the area of diagnostics of single-nucleotide genetic changes. This is the second patent application filed by the company in the area of oncological diagnostics.
